Reaction
Ocular Hypertension reporting signals
As of the last recalculation, Ocular Hypertension appears in 1,891 FAERS reports alongside 36 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 61.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ranibizumab | 138 | 61.6 | 62.0 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 100 | 49.6 | 49.8 |
| Faricimab | 35 | 48.4 | 48.6 |
| Aflibercept | 115 | 43.1 | 43.3 |
| Triamcinolone Acetonide | 107 | 40.3 | 40.5 |
| Prednisolone Acetate | 37 | 40.1 | 40.3 |
| Brimonidine Tartrate | 47 | 29.8 | 29.8 |
| Brinzolamide | 21 | 26.9 | 27.0 |
| Dorzolamide Hydrochloride And Timolol Maleate | 19 | 26.7 | 26.8 |
| Timolol Maleate | 19 | 21.3 | 21.4 |
| Atropine | 15 | 20.1 | 20.1 |
| Timolol | 21 | 19.3 | 19.4 |
| Atropine Sulfate | 18 | 18.5 | 18.5 |
| Travoprost | 14 | 17.9 | 18.0 |
| Tobramycin Solution | 19 | 17.6 | 17.6 |
| Tobramycin Sulfate | 19 | 17.1 | 17.1 |
| Latanoprost | 63 | 14.2 | 14.2 |
| Moxifloxacin Hydrochloride | 24 | 13.2 | 13.2 |
| Tobramycin | 24 | 11.1 | 11.1 |
| Moxifloxacin | 13 | 10.2 | 10.2 |
| Bimatoprost | 26 | 10.1 | 10.1 |
| Adalimumab-Adaz | 47 | 10.0 | 10.0 |
| Cefazolin | 8 | 9.7 | 9.7 |
| Adalimumab-Aaty | 37 | 8.8 | 8.8 |
| Adalimumab-Fkjp | 36 | 8.7 | 8.7 |
| Prednisolone | 128 | 8.3 | 8.3 |
| Prednisolone Oral | 128 | 8.3 | 8.3 |
| Prednisolone Oral Solution | 128 | 8.3 | 8.3 |
| Carboxymethylcellulose Sodium | 7 | 8.2 | 8.2 |
| Dexamethasone | 175 | 7.1 | 7.1 |
| Epoprostenol | 8 | 6.8 | 6.8 |
| Bevacizumab | 68 | 6.2 | 6.2 |
| Cariprazine | 3 | 3.6 | 3.6 |
| Minoxidil Foam 5% (Womens) | 10 | 3.3 | 3.3 |
| Lifitegrast | 4 | 2.7 | 2.7 |
| Minoxidil | 10 | 2.5 | 2.5 |